EIKN (NASDAQ:EIKN) Coverage Initiated at Morgan Stanley

Investment analysts at Morgan Stanley initiated coverage on shares of EIKN (NASDAQ:EIKN) in a report issued on Monday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $32.00 price target on the stock. Morgan Stanley’s price objective points to a potential upside of 131.88% from the stock’s previous close.

A number of other research firms have also recently commented on EIKN. Mizuho started coverage on shares of EIKN in a research note on Monday. They set an “outperform” rating and a $26.00 target price on the stock. Bank of America began coverage on shares of EIKN in a research report on Monday. They set a “buy” rating and a $34.00 price objective on the stock. Wall Street Zen upgraded shares of EIKN to a “hold” rating in a research note on Monday, February 16th. Finally, Wedbush initiated coverage on EIKN in a research note on Thursday, February 26th. They issued an “underperform” rating and a $7.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.60.

EIKN Stock Down 7.3%

EIKN stock opened at $13.80 on Monday. EIKN has a twelve month low of $13.28 and a twelve month high of $17.40.

EIKN News Summary

Here are the key news stories impacting EIKN this week:

• Positive Sentiment: Multiple major brokerages initiated coverage with bullish ratings and high price targets — Morgan Stanley started coverage with an “overweight” and $32 PT. Article Title
• Positive Sentiment: Bank of America initiated coverage with a “buy” rating and a $34 price target (largest upside among the reported PTs). Article Title
• Positive Sentiment: JPMorgan also initiated coverage with an “overweight” rating and a $29 price target. Article Title
• Positive Sentiment: Mizuho started coverage with an “outperform” rating and a $26 price target. Article Title
• Positive Sentiment: Cantor Fitzgerald added coverage with an “overweight” rating as well, adding to the cluster of institutional bullish views. Article Title
• Neutral Sentiment: Reported short‑interest figures are inconsistent/likely erroneous (entries show 0 shares and NaN changes, with a days‑to‑cover of 0.0), so short‑squeeze or large short‑covering dynamics are not substantiated by the available data.
• Negative Sentiment: Despite the bullish analyst activity, shares moved lower on light trading (reported intraday volume ~144k vs. average ~403k) and trade near the 12‑month low region (~$13.28 low, $17.40 high), suggesting limited buying follow‑through and possible near‑term profit‑taking or broader market pressure.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.